Sandoz And Amgen Resolve Patent Disputes Over FDA-Approved Denosumab Biosimilars In The US
Sandoz And Amgen Resolve Patent Disputes Over FDA-Approved Denosumab Biosimilars In The US
山德士和安進在美國解決有關美國食品藥品管理局批准的Denosumab生物仿製藥的專利糾紛
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
山德士與安進達成協議，解決與其美國denosumab生物仿製藥有關的所有專利訴訟
- Agreement clears path for launch of Jubbonti and Wyost on May 31, 2025 or earlier under certain circumstances
- Jubbonti and Wyost are first and only FDA-approved biosimilars to and interchangeable with Prolia* and Xgeva*
- Anticipated launch further strengthens Sandoz biosimilar portfolio and advances growth strategy
- 協議爲在某些情況下於2025年5月31日或更早推出Jubbonti和Wyost掃清了道路
- Jubbonti 和 Wyost 是美國食品藥品管理局批准的第一款也是唯一一款可與 Prolia* 和 Xgeva* 互換的生物仿製藥
- 預期的推出進一步強化了山德士生物仿製藥產品組合並推進了增長戰略